Investors in Savara are bracing themselves for the company's upcoming earnings announcement, which is set to take place as the firm awaits a crucial FDA review. The review is a significant development for Savara, and investors will be closely watching the company's financial results to gauge its prospects.
Savara investors await earnings ahead of FDA review
UKPulse Money DeskInvestors in Savara are preparing for the company's earnings announcement, which comes as the firm awaits a crucial FDA review.
- Savara's earnings are due to be announced
- The company is awaiting a crucial FDA review
What this means for you: If you hold Savara shares, you may want to monitor the company's earnings announcement and the outcome of the FDA review.